Download PDF
CC BY 4.0 · Journal of Health and Allied Sciences NU 2024; 14(04): 527-531
DOI: 10.1055/s-0044-1779614
Original Article

Therapeutic Benefits of N-Acetylcysteine in the Management of Contrast-Induced Nephropathy

Sivakumar Velusamy 
1   Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India
,
Rama Parthasarathy
1   Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India
,
Jessica Jayakumar 
1   Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India
,
Dharshini Parthiban
1   Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective This study aimed to assess the beneficial effects of N-acetylcysteine (NAC) in the treatment of contrast-induced nephropathy (CIN).

Materials and Methods A prospective study was conducted in the department of cardiology of a tertiary health care hospital. A sample of 100 patients who had developed CIN through coronary angioplasty were categorized into two groups: one group treated with intravenous fluids (IVF) monotherapy and the other group treated with the combination of IVF and NAC therapy.

Statistical Analysis The data were analyzed using statistical software SPSS software version 26 and statistical significance was set at p < 0.05. Independent t-test and paired t-test were used to analyze the parameters.

Results The rate of incidence of CIN was found to be 10%. We observed that the IVF + NAC combination therapy significantly decreases the serum creatinine compared to IVF monotherapy (p = 0.004). Both therapies show similar treatment outcomes with no significant difference (p = 0.556) in the case of estimated glomerular filtration rate (eGFR). Based on creatinine clearance, the results show adding NAC does not impact any additional benefits (p = 000). The duration of hospital stay of the NAC group was reduced significantly (p = 0.000).

Conclusion At present, we found that the treatment outcomes which we analyzed based on factors such as serum creatinine, eGFR, and creatinine clearance, are too inconsistent to conclude the beneficial effect of NAC in the management of CIN.

Keywords

contrast-induced nephropathy - creatinine clearance - duration of hospital stay - eGFR - N-acetylcysteine - serum creatinine

Ethics Approval

The study was approved by the PSG Institutional Human Ethics Committee. The approval date and number are February 14, 2018 and IHEC # 086, respectively. Due to the retrospective study design, a waiver of the informed consent was obtained.


Declaration

The study was performed in accordance with the Declaration of Helsinki.




Publication History

Article published online:
26 March 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Samadian F, Dalili N, Mahmoudieh L, Ziaei S. Contrast-induced nephropathy: essentials and concerns. Iran J Kidney Dis 2018; 12 (03) 135-141
    PubMedSearch in Google Scholar
  • 2 Boozari M, Hosseinzadeh H. Preventing contrast-induced nephropathy (CIN) with herbal medicines: a review. Phytother Res 2021; 35 (03) 1130-1146
    CrossrefPubMedSearch in Google Scholar
  • 3 Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004; 183 (06) 1673-1689
    CrossrefPubMedSearch in Google Scholar
  • 4 Delanaye P, Jager KJ, Bökenkamp A. et al. CKD: a call for an age-adapted definition. J Am Soc Nephrol 2019; 30 (10) 1785-1805
    CrossrefPubMedSearch in Google Scholar
  • 5 Guo Z, Liu J, Lei L. et al. Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2020; 10 (10) e039009
    CrossrefPubMedSearch in Google Scholar
  • 6 Barrios López A, García Martínez F, Rodríguez JI. et al. Incidence of contrast-induced nephropathy after a computed tomography scan. Radiología (Engl Ed) 2021; 63 (04) 307-313
    CrossrefPubMedSearch in Google Scholar
  • 7 Feng Y, Huang X, Li L, Chen Z. N-acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: a meta-analysis. Nephrology (Carlton) 2018; 23 (06) 530-538
    CrossrefPubMedSearch in Google Scholar
  • 8 Marenzi G, Assanelli E, Marana I. et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354 (26) 2773-2782
    CrossrefPubMedSearch in Google Scholar
  • 9 Briguori C, Colombo A, Violante A. et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004; 25 (03) 206-211
    CrossrefPubMedSearch in Google Scholar
  • 10 Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 2009; 122 (09) 874.e9-874.e15
    CrossrefPubMedSearch in Google Scholar
  • 11 Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15 (02) 407-410
    CrossrefPubMedSearch in Google Scholar